Jeffrey C. Lightcap
Known title: DirectorCIK: 0001519465
Jeffrey C. Lightcap's purchase track record
Jeffrey C. Lightcap has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 12/16/2025 | HTFL | $1.05M | -14.9% | +21.1% | +10.5% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| HTFL | ▲ Buy | Option Exercise | 47,420 | $901K | 7/24/2026 | View on chart |
| HTFL | ▼ Sell | Other | 206,261 | $0 | 3/24/2026 | View on chart |
| HTFL | ▲ Buy | Open Market | 40,000 | $1.1M | 12/16/2025 | View on chart |
| HTFL | ▼ Sell | Other | 833,075 | — | 8/11/2025 | View on chart |
| HTFL | ▼ Sell | Other | 1,248,939 | — | 8/11/2025 | View on chart |
| HTFL | ▼ Sell | Other | 4,615,542 | — | 8/11/2025 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
Heartflow featured in AI healthcare stock roundup
Heartflow was included in a recent Yahoo Finance article highlighting top AI healthcare stocks alongside Pfizer and another company. This mention places the firm in the conversation regarding artificial intelligence applications in the medical sector. The stock currently trades within its 52-week range, with analysts maintaining an average price target of $46.00.
Heartflow featured in AI healthcare stock roundup. Heartflow was included in a recent Yahoo Finance article highlighting top AI healthcare stocks alongside Pfizer and another company. This mention places the firm in the conversation regarding artificial intelligence applications in the medical sector. The stock currently trades within its 52-week range, with analysts maintaining an average price target of $46.00.